Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06586671 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)
A Phase 1 study of Hematological Malignancy, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06586671 is a Phase 1 study of Hematological Malignancy that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 40 participants, below the 117-participant average among 9 other Hematological Malignancy trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06586671, a Phase 1 study of Hematological Malignancy, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the study is to measure and compare the levels of nemtabrutinib in the blood after taking different forms of nemtabrutinib orally on an empty stomach (fasted) to see if they are the same or different.
Conditions Studied
Interventions
- DRUG Nemtabrutinib
Study Locations (1)
Florida
- QPS-MRA, LLC-Early Phase (Site 0002) - South Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-08-28 |
| Est. Completion | 2023-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06586671
The ClinicalTrials.gov registry entry for NCT06586671 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 117-participant average among 9 other Hematological Malignancy trials with a reported enrollment target (66% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematological Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Nemtabrutinib is the first listed.
NCT06586671 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06586671 about?
NCT06586671 is a clinical study titled "A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)". The goal of the study is to measure and compare the levels of nemtabrutinib in the blood after taking different forms of nemtabrutinib orally on an empty stomach (fasted) to see if they are the same or different.
What is the current status of trial NCT06586671?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-08-28. Estimated completion is 2023-11-13.
What conditions does trial NCT06586671 study?
This clinical trial studies the following conditions: Hematological Malignancy.
What interventions are being tested in trial NCT06586671?
The interventions under investigation include: Nemtabrutinib (DRUG).
Who is sponsoring clinical trial NCT06586671?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06586671 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
RECRUITING · Phase 1
-
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
COMPLETED · Phase 1
-
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
RECRUITING · Phase 2
-
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
RECRUITING · Phase 2
-
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
RECRUITING
-
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.